{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:20:18Z","timestamp":1772234418785,"version":"3.50.1"},"reference-count":155,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.3892\/ol.2017.5712","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T02:05:26Z","timestamp":1486692326000},"page":"2003-2014","source":"Crossref","is-referenced-by-count":39,"title":["What is known about melatonin, chemotherapy and altered gene expression in breast cancer"],"prefix":"10.3892","volume":"13","author":[{"given":"Carlos","family":"Mart\u00ednez-Campa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Men\u00e9ndez-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Alonso-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"\u00c1lvarez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Cos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"key20180108112730_b1-ol-0-0-5712","year":"2016","journal-title":"Second Expert Report"},{"key":"key20180108112730_b2-ol-0-0-5712","year":"2015","journal-title":"Cancer facts and figures"},{"key":"key20180108112730_b3-ol-0-0-5712","year":"2016","journal-title":"What are the key statistics about breast cancer?"},{"key":"key20180108112730_b4-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/jnci\/91.9.750","article-title":"Declining breast cancer mortality: What's behind it?","volume":"91","author":"Reynolds","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"key20180108112730_b5-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogens plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"J Am Med Assoc"},{"key":"key20180108112730_b6-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00049527","article-title":"Shaping future strategies for the pharmacological control of tumor cell metastases","volume":"5","author":"Greig","year":"1986","journal-title":"Cancer Metastasis Rev"},{"key":"key20180108112730_b7-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.me.28.020177.002355","article-title":"Surgical adjuvant chemotherapy","volume":"28","author":"Perloff","year":"1977","journal-title":"Ann Rev Med"},{"key":"key20180108112730_b8-ol-0-0-5712","first-page":"1339","article-title":"Treatment of breast cancer","volume":"81","author":"Maughan","year":"2010","journal-title":"Am Fam Physician"},{"key":"key20180108112730_b9-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1245\/s10434-015-4406-6","article-title":"Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer","volume":"22","author":"Mamounas","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"key20180108112730_b10-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1745505716677139","article-title":"Neoadjuvant chemotherapy in breast cancers","volume":"12","author":"Masood","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"key20180108112730_b11-ol-0-0-5712","first-page":"241","article-title":"The molecular genetics of breast cancer and targeted therapy","volume":"1","author":"Suter","year":"2007","journal-title":"Biologics"},{"key":"key20180108112730_b12-ol-0-0-5712","unstructured":"BreastCancer.OrgHow is Chemotherapy Given?http:\/\/www.breastcancer.org\/treatment\/chemotherapy\/process\/howAugust142016"},{"key":"key20180108112730_b13-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108112730_b14-ol-0-0-5712","first-page":"1231","article-title":"Vinca alcaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"Int J Prev Med"},{"key":"key20180108112730_b15-ol-0-0-5712","first-page":"1390","article-title":"The Vinca Alkaloids: A new class of oncolytic agents","volume":"23","author":"Johnson","year":"1963","journal-title":"Cancer Res"},{"key":"key20180108112730_b16-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0163-7258(91)90081-V","article-title":"Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules","volume":"51","author":"Himes","year":"1991","journal-title":"Pharmacol Ther"},{"key":"key20180108112730_b17-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature03566","article-title":"Structural basis for the regulation of tubulin by vinblastine","volume":"435","author":"Gigant","year":"2005","journal-title":"Nature"},{"key":"key20180108112730_b18-ol-0-0-5712","first-page":"385","article-title":"Amorphous taxine & crystalline taxine A; Taxus alkaloids. II","volume":"96","author":"Graf","year":"1957","journal-title":"Pharm Zentralhalle Dtschl"},{"key":"key20180108112730_b19-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agentes. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agente from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J Am Chem Soc"},{"key":"key20180108112730_b20-ol-0-0-5712","first-page":"2486","article-title":"Phase I clinical and pharmacokinetic study of taxol","volume":"47","author":"Wiernik","year":"1987","journal-title":"Cancer Res"},{"key":"key20180108112730_b21-ol-0-0-5712","first-page":"4845","article-title":"Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue","volume":"51","author":"Bissery","year":"1991","journal-title":"Cancer Res"},{"key":"key20180108112730_b22-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"key20180108112730_b23-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1073\/pnas.0603704103","article-title":"Insights into the mechanism of microtubule stabilization by Taxol","volume":"103","author":"Xiao","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108112730_b24-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1073\/pnas.051309398","article-title":"The binding conformation of Taxol in beta-tubulin: A model based on electron crystallographic density","volume":"98","author":"Snyder","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108112730_b25-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1985.3.6.818","article-title":"A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer","volume":"3","author":"Jain","year":"1985","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b26-ol-0-0-5712","first-page":"1542","article-title":"Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis","volume":"35","author":"Mizuno","year":"1975","journal-title":"Cancer Res"},{"key":"key20180108112730_b27-ol-0-0-5712","first-page":"1526","article-title":"Inhibitors of DNA topoisomerases","volume":"24","author":"Andoh","year":"1997","journal-title":"Gan To Kagaku Ryoho"},{"key":"key20180108112730_b28-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2011.12.012","article-title":"Epirubicin: Is it like doxorubicin in breast cancer? A clinical review","volume":"21","author":"Khasraw","year":"2012","journal-title":"Breast"},{"key":"key20180108112730_b29-ol-0-0-5712","year":"2016","journal-title":"Advisory Committees: 2010 Meeting Materials, Oncologic Drugs Advisory Committee"},{"key":"key20180108112730_b30-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res"},{"key":"key20180108112730_b31-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"e000036","DOI":"10.1136\/esmoopen-2016-000036","article-title":"Recent developments and translational aspects in targeted therapy for metastatic breast cancer","volume":"1","author":"Marhold","year":"2016","journal-title":"ESMO Open"},{"key":"key20180108112730_b32-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1523-5394.1999.07108.x","article-title":"Drug update: Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer","volume":"7","author":"Wong","year":"1999","journal-title":"Cancer Pract"},{"key":"key20180108112730_b33-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b34-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3816\/CBC.2009.s.005","article-title":"Treatment of HER2-positive metastatic breast cancer following initial progression","volume":"9","author":"Mayer","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"key20180108112730_b35-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","article-title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGR103009, a phase II study","volume":"10","author":"Kaufman","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108112730_b36-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b37-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1634\/theoncologist.9-suppl_3-10","article-title":"Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR\/ErbB-2 inhibitor lapatinib","volume":"9","author":"Burris","year":"2004","journal-title":"Oncologist"},{"key":"key20180108112730_b38-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b39-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res"},{"key":"key20180108112730_b40-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/478334b","article-title":"Chemical biology: Many faces of a cancer-supporting protein","volume":"478","author":"Darby","year":"2011","journal-title":"Nature"},{"key":"key20180108112730_b41-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.2174\/1381612822666160325152200","article-title":"Current understanding of HSP90 as a novel therapeutic target: An emerging approach for the treatment of cancer","volume":"22","author":"Hague","year":"2016","journal-title":"Curr Pharm Des"},{"key":"key20180108112730_b42-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.imlet.2005.11.018","article-title":"Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1","volume":"104","author":"Zsebik","year":"2006","journal-title":"Immunol Lett"},{"key":"key20180108112730_b43-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.cad.0000136876.11928.be","article-title":"Hsp90: An emerging target for breast cancer therapy","volume":"15","author":"Beliakoff","year":"2004","journal-title":"Anticancer Drugs"},{"key":"key20180108112730_b44-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fcell.2016.00027","article-title":"Overcoming hypoxia-mediated tumor progression: Combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction","volume":"4","author":"McDonald","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"key20180108112730_b45-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/aps.2015.73","article-title":"Novel endogenous angiogenesis inhibitors and their therapeutic potential","volume":"36","author":"Rao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"key20180108112730_b46-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"21247","DOI":"10.18632\/oncotarget.6918","article-title":"VEGF pathway targeting agents, vessel normalization and tumor drug uptake: From bench to bedside","volume":"7","author":"Arjaans","year":"2016","journal-title":"Oncotarget"},{"key":"key20180108112730_b47-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10911-012-9266-0","article-title":"Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer","volume":"17","author":"Kerbel","year":"2012","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"key20180108112730_b48-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ncponc0026","article-title":"Targeting angiogenesis in cancer: Clinical development of bevacizumab","volume":"1","author":"Kerr","year":"2004","journal-title":"Nat Clin Pract Oncol"},{"key":"key20180108112730_b49-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ctrv.2011.12.002","article-title":"Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials","volume":"38","author":"Mackey","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"key20180108112730_b50-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b51-ol-0-0-5712","first-page":"1324","article-title":"Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy","volume":"9","author":"Sloan","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"key20180108112730_b52-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","article-title":"Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis","volume":"17","author":"Gril","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180108112730_b53-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1634\/theoncologist.2010-0081","article-title":"A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the princess Margaret Hospital phase II consortium","volume":"15","author":"Taylor","year":"2010","journal-title":"Oncologist"},{"key":"key20180108112730_b54-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1749-6632.1986.tb16002.x","article-title":"Estradiol\/progesterone interaction in normal and pathological breast cells","volume":"464","author":"Mauvais-Jarvis","year":"1986","journal-title":"Ann N Acad Sci"},{"key":"key20180108112730_b55-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast-cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J Biol Chem"},{"key":"key20180108112730_b56-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14740338.2015.1014799","article-title":"Selective estrogen receptor modulators in clinical practice: A safety overview","volume":"14","author":"Ellis","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"key20180108112730_b57-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-14-0092","article-title":"Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer","volume":"21","author":"Jordan","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"key20180108112730_b58-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.breast.2014.09.006","article-title":"Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer","volume":"23","author":"Dalmau","year":"2014","journal-title":"Breast"},{"key":"key20180108112730_b59-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1677\/erc.0.0090267","article-title":"Fulvestrant (\u2018Faslodex\u2019)-a new treatment option for patients progressing on prior endocrine therapy","volume":"9","author":"Morris","year":"2002","journal-title":"Endocr Relat Cancer"},{"key":"key20180108112730_b60-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/092986710790820633","article-title":"Fulvestrant-a novel endocrine therapy for breast cancer","volume":"17","author":"Johnston","year":"2010","journal-title":"Curr Med Chem"},{"key":"key20180108112730_b61-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.bjc.6601508","article-title":"First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen?","volume":"90","author":"Wong","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180108112730_b62-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0079-6123(08)81008-4","article-title":"Melatonin: A multitasking molecule","volume":"181","author":"Reiter","year":"2010","journal-title":"Prog Brain Res"},{"key":"key20180108112730_b63-ol-0-0-5712","first-page":"325","article-title":"Melatonin: Exceeding expectations","volume":"29","author":"Reiter","year":"2014","journal-title":"Physiology (Bethesda)"},{"key":"key20180108112730_b64-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-15-0030","article-title":"Melatonin: An inhibitor of breast cancer","volume":"22","author":"Hill","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"key20180108112730_b65-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0303-7207(01)00449-X","article-title":"Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin","volume":"176","author":"Dai","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"key20180108112730_b66-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/978-1-4615-0135-0_62","article-title":"Melatonin: Detoxification of oxygen and nitrogen-based toxic reactants","volume":"527","author":"Reiter","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"key20180108112730_b67-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/BF01613283","article-title":"Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo","volume":"117","author":"Blask","year":"1991","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180108112730_b68-ol-0-0-5712","first-page":"284","article-title":"Melatonin and malignant disease","volume":"117","author":"Tamarkin","year":"1985","journal-title":"Ciba Found Symp"},{"key":"key20180108112730_b69-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0959-8049(05)80087-5","article-title":"Breast cancer, blindness and melatonin","volume":"28","author":"Coleman","year":"1992","journal-title":"Eur J Cancer"},{"key":"key20180108112730_b70-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1054\/bjoc.2000.1617","article-title":"Risk of breast cancer among norwegian women with visual impairment","volume":"84","author":"Kliukiene","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180108112730_b71-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10552-009-9405-0","article-title":"Total visual blindness is protective against breast cancer","volume":"20","author":"Flynn-Evans","year":"2009","journal-title":"Cancer Causes Control"},{"key":"key20180108112730_b72-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/jnci\/93.20.1563","article-title":"Rotating night shifts and risk of breast cancer in women participating in the nurses' health study","volume":"93","author":"Schernhammer","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"key20180108112730_b73-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-079X.2008.00559.x","article-title":"Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells","volume":"45","author":"Gonz\u00e1lez","year":"2008","journal-title":"J Pineal Res"},{"key":"key20180108112730_b74-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cdp.2006.03.002","article-title":"Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions","volume":"30","author":"Cos","year":"2006","journal-title":"Cancer Detect Prev"},{"key":"key20180108112730_b75-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-005-9006-x","article-title":"Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells","volume":"94","author":"Mart\u00ednez-Campa","year":"2005","journal-title":"Breast Cancer Rse Treat"},{"key":"key20180108112730_b76-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-079X.2004.00186.x","article-title":"Melatonin modulates aromatase activity in MCF-7 human breast cancer cells","volume":"38","author":"Cos","year":"2005","journal-title":"J Pineal Res"},{"key":"key20180108112730_b77-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mce.2011.06.012","article-title":"Steroid sulfatase: A pivotal player in estrogen synthesis and metabolism","volume":"340","author":"Purohit","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"key20180108112730_b78-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2325\/jbcs.13.129","article-title":"New development in intracrinology of breast carcinoma","volume":"13","author":"Sasano","year":"2006","journal-title":"Breast Cancer"},{"key":"key20180108112730_b79-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/156800908786733469","article-title":"Melatonin as a selective estrogen enzyme modulator","volume":"8","author":"Cos","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180108112730_b80-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3892\/or.2013.2314","article-title":"Melatonin modulates aromatase activity and expression in endothelial cells","volume":"29","author":"\u00c1lvarez-Garc\u00eda","year":"2013","journal-title":"Oncol Rep"},{"key":"key20180108112730_b81-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/156800910791190201","article-title":"In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin","volume":"10","author":"Gonz\u00e1lez","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180108112730_b82-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3892\/ijmm.2015.2360","article-title":"Melatonin affects the dynamic steady-state equilibrium of estrogen sulfates in human umbilical vein endothelial cells by regulating the balance between estrogen sulfatase and sulfotransferase","volume":"36","author":"Gonz\u00e1lez","year":"2015","journal-title":"Int J Mol Med"},{"key":"key20180108112730_b83-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-079X.2004.00207.x","article-title":"Melatonin-estrogen interactions in breast cancer","volume":"38","author":"S\u00e1nchez-Barcel\u00f3","year":"2005","journal-title":"J Pineal Res"},{"key":"key20180108112730_b84-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/mend.16.5.0830","article-title":"Calmodulin is a selective modulator of estrogen receptors","volume":"16","author":"Garc\u00eda Pedrero","year":"2002","journal-title":"Mol Endocrinol"},{"key":"key20180108112730_b85-ol-0-0-5712","first-page":"1681","article-title":"Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells","volume":"8","author":"Molis","year":"1994","journal-title":"Mol Endocrinol"},{"key":"key20180108112730_b86-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1096\/fasebj.13.8.857","article-title":"Melatonin blocks the activation of estrogen receptor for DNA binding","volume":"13","author":"Rato","year":"1999","journal-title":"FASEB J"},{"key":"key20180108112730_b87-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1006\/bbrc.1996.1564","article-title":"Calmodulin decreases the estrogen binding capacity of the estrogen receptor","volume":"227","author":"Bouhoute","year":"1996","journal-title":"Biochem Bioph Res Commun"},{"key":"key20180108112730_b88-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"38294","DOI":"10.1074\/jbc.M403140200","article-title":"Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin","volume":"279","author":"del R\u00edo","year":"2004","journal-title":"J Biol Chem"},{"key":"key20180108112730_b89-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0304-3835(01)00873-4","article-title":"Involvement of the mt1 melatonin receptor in human breast cancer","volume":"179","author":"Ram","year":"2002","journal-title":"Cancer Lett"},{"key":"key20180108112730_b90-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/1T4V-CT1G-UBJP-3EHP","article-title":"Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue","volume":"118","author":"Dillon","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"key20180108112730_b91-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1073\/pnas.91.18.8517","article-title":"Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription","volume":"91","author":"Aronica","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108112730_b92-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/endo.138.1.4824","article-title":"The Mel1a melatonin receptor is coupled to parallel signal transduction pathways","volume":"138","author":"Godson","year":"1997","journal-title":"Endocrinology"},{"key":"key20180108112730_b93-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0304-3835(92)90050-6","article-title":"The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system","volume":"64","author":"Hill","year":"1992","journal-title":"Cancer Lett"},{"key":"key20180108112730_b94-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-079X.1994.tb00110.x","article-title":"Melatonin modulates growth factor activity in MCF-7 human breast cancer cells","volume":"17","author":"Cos","year":"1994","journal-title":"J Pineal Res"},{"key":"key20180108112730_b95-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-079X.1995.tb00146.x","article-title":"Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer","volume":"18","author":"Molis","year":"1995","journal-title":"J Pineal Res"},{"key":"key20180108112730_b96-ol-0-0-5712","first-page":"1025","article-title":"Differential effects of estradiol and its analogs on cyclin D1 and CDK4 expression in estrogen receptor positive MCF-7 and estrogen receptor-transfected MCF-10AEwt5 cells","volume":"5","author":"Hong","year":"1998","journal-title":"Oncol Rep"},{"key":"key20180108112730_b97-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-079X.1991.tb00007.x","article-title":"Effects of melatonin on the cell kinetics and \u2018estrogen-rescue\u2019 of MCF-7 human breast cancer cells in culture","volume":"10","author":"Cos","year":"1991","journal-title":"J Pineal Res"},{"key":"key20180108112730_b98-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0024-3205(99)00262-3","article-title":"Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro","volume":"65","author":"Mediavilla","year":"1999","journal-title":"Life Sci"},{"key":"key20180108112730_b99-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2015.10.015","article-title":"Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis","volume":"370","author":"Alonso-Gonz\u00e1lez","year":"2016","journal-title":"Cancer Lett"},{"key":"key20180108112730_b100-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/bbrc.1997.6544","article-title":"Changes in BRCA2 expression during progression of the cell cycle","volume":"234","author":"Wang","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108112730_b101-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1034\/j.1600-079X.2003.00077.x","article-title":"Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivoin vitro","volume":"35","author":"Leon-Blanco","year":"2003","journal-title":"J Pineal Res"},{"key":"key20180108112730_b102-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2008.04.001","article-title":"Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells","volume":"268","author":"Mart\u00ednez-Campa","year":"2008","journal-title":"Cancer Lett"},{"key":"key20180108112730_b103-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.toxlet.2008.07.021","article-title":"Melatonin modulates the cadmium-induced expression of MT-2 and MT-1 metallothioneins in three lines of human tumor cells (MCF-7, MDA-MB-231 and HeLa)","volume":"181","author":"Alonso-Gonz\u00e1lez","year":"2008","journal-title":"Toxicol Lett"},{"key":"key20180108112730_b104-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/bcr2794","article-title":"Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway","volume":"12","author":"Mao","year":"2010","journal-title":"Breast Cancer Res"},{"key":"key20180108112730_b105-ol-0-0-5712","first-page":"4383","article-title":"Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells","volume":"58","author":"Cos","year":"1998","journal-title":"Cancer Res"},{"key":"key20180108112730_b106-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1568006053005038","article-title":"Cancer metastasis: Characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates","volume":"5","author":"Kawaguchi","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"key20180108112730_b107-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1242\/jcs.100115","article-title":"E-cadherin-integrin crosstalk in cancer invasion and metastasis","volume":"126","author":"Canel","year":"2013","journal-title":"J Cell Sci"},{"key":"key20180108112730_b108-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjc.1997.113","article-title":"Altered cell-matrix contact: A prerequisite for breast cancer metastasis?","volume":"75","author":"Gui","year":"1997","journal-title":"Br J Cancer"},{"key":"key20180108112730_b109-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-079X.2011.00911.x","article-title":"Melatonin promotes differentiation of 3T3-L1 fibroblasts","volume":"52","author":"Gonz\u00e1lez","year":"2012","journal-title":"J Pineal Res"},{"key":"key20180108112730_b110-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-079X.2011.00940.x","article-title":"Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production","volume":"52","author":"Alvarez-Garc\u00eda","year":"2012","journal-title":"J Pineal Res"},{"key":"key20180108112730_b111-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jpi.12007","article-title":"Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells","volume":"54","author":"Alvarez-Garc\u00eda","year":"2013","journal-title":"J Pineal Res"},{"key":"key20180108112730_b112-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"23536","DOI":"10.1074\/jbc.M400554200","article-title":"Heparanase induces endothelial cell migration via protein kinase B\/Akt activation","volume":"279","author":"Gingis-Velitski","year":"2004","journal-title":"J Biol Chem"},{"key":"key20180108112730_b113-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1667\/RR3158","article-title":"Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K\/AKT pathway and induction of phosphorylation of BAD","volume":"161","author":"Gu","year":"2004","journal-title":"Radiat Res"},{"key":"key20180108112730_b114-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mvr.2013.02.008","article-title":"Antiangiogenic effects of melatonin in endothelial cell cultures","volume":"87","author":"Alvarez-Garc\u00eda","year":"2013","journal-title":"Microvasc Res"},{"key":"key20180108112730_b115-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejmech.2015.08.010","article-title":"Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer","volume":"102","author":"Ahmad","year":"2015","journal-title":"Eur J Med Chem"},{"key":"key20180108112730_b116-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/ol.2014.2203","article-title":"Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review)","volume":"8","author":"Cos","year":"2014","journal-title":"Oncol Lett"},{"key":"key20180108112730_b117-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00018-012-1161-8","article-title":"Molecular mechanisms of melatonin's inhibitory actions on breast cancers","volume":"70","author":"Proietti","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"key20180108112730_b118-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/030089168707300508","article-title":"Clinical study of melatonin in untreatable advanced cancer patients","volume":"73","author":"Lissoni","year":"1987","journal-title":"Tumori"},{"key":"key20180108112730_b119-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/S1462399409000982","article-title":"Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives","volume":"11","author":"Grant","year":"2009","journal-title":"Expert Rev Mol Med"},{"key":"key20180108112730_b120-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2012.43.6766","article-title":"Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo controlled trial","volume":"31","author":"Del Fabbro","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b121-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ijrobp.2007.01.012","article-title":"Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)","volume":"68","author":"Berk","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108112730_b122-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01262569","article-title":"Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin","volume":"5","author":"Lissoni","year":"1997","journal-title":"Support Care Cancer"},{"key":"key20180108112730_b123-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2002.11.004","article-title":"Melatonin: From basic research to cancer treatment clinics","volume":"20","author":"Vijayalaxmi","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108112730_b124-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s005200100281","article-title":"Is there a role for melatonin in supportive care?","volume":"10","author":"Lissoni","year":"2002","journal-title":"Support Care Cancer"},{"key":"key20180108112730_b125-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0959-8049(99)00159-8","article-title":"Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status","volume":"35","author":"Lissoni","year":"1999","journal-title":"Eur J Cancer"},{"key":"key20180108112730_b126-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-079X.2003.00032.x","article-title":"Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial","volume":"35","author":"Lissoni","year":"2003","journal-title":"J Pineal Res"},{"key":"key20180108112730_b127-ol-0-0-5712","first-page":"7327","article-title":"Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial","volume":"34","author":"Sookprasert","year":"2014","journal-title":"Anticancer Res"},{"key":"key20180108112730_b128-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1534735411425484","article-title":"Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials","volume":"11","author":"Seely","year":"2012","journal-title":"Integr Cancer Ther"},{"key":"key20180108112730_b129-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00280-012-1828-8","article-title":"The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108112730_b130-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jsbmb.2006.09.004","article-title":"The role of estrogen in the initiation of breast cancer","volume":"102","author":"Russo","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180108112730_b131-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ajpath.2016.02.023","article-title":"Genomic and epigenomic alterations in cancer","volume":"186","author":"Chakravarthi","year":"2016","journal-title":"Am J Pathol"},{"key":"key20180108112730_b132-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-079X.2011.00896.x","article-title":"MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect","volume":"51","author":"Lee","year":"2011","journal-title":"J Pineal Res"},{"key":"key20180108112730_b133-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1600-079X.2012.01027.x","article-title":"Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin","volume":"54","author":"Lee","year":"2013","journal-title":"J Pineal Res"},{"key":"key20180108112730_b134-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1158\/0008-5472.CAN-13-3156","article-title":"Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer","volume":"74","author":"Dauchy","year":"2014","journal-title":"Cancer Res"},{"key":"key20180108112730_b135-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jpi.12239","article-title":"Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal","volume":"59","author":"Xiang","year":"2015","journal-title":"J Pineal Res"},{"key":"key20180108112730_b136-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/092986711794839197","article-title":"Structural and functional properties of human multidrug resistance protein 1 (MRP1\/ABCC1)","volume":"18","author":"He","year":"2011","journal-title":"Curr Med Chem"},{"key":"key20180108112730_b137-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1034\/j.1600-079X.2001.310303.x","article-title":"Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells","volume":"31","author":"Granzotto","year":"2001","journal-title":"J Pineal Res"},{"key":"key20180108112730_b138-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"e85311","DOI":"10.1371\/journal.pone.0085311","article-title":"Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer","volume":"9","author":"Jardim-Perassi","year":"2014","journal-title":"PLoS One"},{"key":"key20180108112730_b139-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jpi.12217","article-title":"Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MDB-231 cells","volume":"58","author":"Woo","year":"2015","journal-title":"J Pineal Res"},{"key":"key20180108112730_b140-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-079X.2012.00973.x","article-title":"Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells","volume":"53","author":"Wang","year":"2012","journal-title":"J Pineal Res"},{"key":"key20180108112730_b141-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jpi.12150","article-title":"Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells","volume":"57","author":"Proietti","year":"2014","journal-title":"J Pineal Res"},{"key":"key20180108112730_b142-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1159\/000366305","article-title":"Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefetinib","volume":"34","author":"Yun","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"key20180108112730_b143-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/cpr.12158","article-title":"Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells","volume":"48","author":"Plaimee","year":"2015","journal-title":"Cell Prolif"},{"key":"key20180108112730_b144-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jpi.12288","article-title":"Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: Effects on oxidative stress and DNA fragmentation","volume":"60","author":"Pariente","year":"2016","journal-title":"J Pineal Res"},{"key":"key20180108112730_b145-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-079X.2012.00974.x","article-title":"Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells","volume":"53","author":"Uguz","year":"2012","journal-title":"J Pineal Res"},{"key":"key20180108112730_b146-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.exphem.2014.11.001","article-title":"Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase","volume":"43","author":"Yamanishi","year":"2015","journal-title":"Exp Hematol"},{"key":"key20180108112730_b147-ol-0-0-5712","first-page":"197","article-title":"Protective and sensitive effects of melatonin combined with Adriamycin on ER+ (estrogen receptor) breast cancer","volume":"36","author":"Ma","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20180108112730_b148-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jpi.12285","article-title":"Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-\u03baB activation","volume":"60","author":"Ju","year":"2016","journal-title":"J Pineal Res"},{"key":"key20180108112730_b149-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00232-015-9855-0","article-title":"Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: Involvement of TRPV1 channels","volume":"249","author":"Kosar","year":"2016","journal-title":"J Membr Biol"},{"key":"key20180108112730_b150-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/ERC-15-0463","article-title":"Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma","volume":"23","author":"Chuffa","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"key20180108112730_b151-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1159\/000438587","article-title":"Melatonin induces cell apoptosis in AGS cells through the activation of JNK and P38 MAPK and the suppression of nuclear factor-kappa B A novel therapeutic implication for gastric cancer","volume":"37","author":"Li","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"key20180108112730_b152-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2014.06.014","article-title":"Melatonin and the circadian system: Contributions to successful female reproduction","volume":"102","author":"Reiter","year":"2014","journal-title":"Fertil Steril"},{"key":"key20180108112730_b153-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"46768","DOI":"10.18632\/oncotarget.8776","article-title":"Melatonin as a potential anticarcinogen for non-small-cell lung cancer","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"key20180108112730_b154-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-015-0438-0","article-title":"Precision medicine in breast cancer: Genes, genomes, and the future of genomically driven treatments","volume":"17","author":"Stover","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"key20180108112730_b155-ol-0-0-5712","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/13543784.2012.681045","article-title":"Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation","volume":"21","author":"Sanchez-Barcelo","year":"2012","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2017.5712\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T10:11:00Z","timestamp":1568801460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.5712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":155,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,2,10]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.3892\/ol.2017.5712"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.5712","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]}}}